Colon cancer is increasing among adults younger than 50 years. However, the prognosis of young-onset colon cancer remains poorly defined given significant age-related demographic, disease, and treatment differences.
S ignificant progress has been made in treating colorectal cancer (CRC) over the past few decades. Among adults 50 years and older, the incidence of CRC has declined by 2% to 3% annually, and CRC survivors now comprise at least 10% of all cancer survivors in the United States. 1, 2 In contrast, among adults younger than 50 years (the current recommended age at which to begin population-based screening), the incidence of CRC since 1975 has steadily increased. 3, 4 Indeed, this persistent rise has been well documented in both population-based and hospital-based nationwide studies, observing annual percentage increases between 1992 and 2005 of 1.5% and between 1998 and 2007 of 2.1%. 3, 4 Although it has been hypothesized that young-onset CRC harbors a distinctive biology, there is currently limited molecular understanding of this potentially unique disease entity. 5, 6 Surgeons are often the first referral physicians treating these young patients. However, at present, the prognosis of young-onset CRC is poorly defined, 6 making it difficult to advise about postoperative treatments and surveillance. The results of some studies 5, 7, 8 suggest poorer survival in the young, while other studies show comparable or better survival relative to patients diagnosed as having later-onset disease. [9] [10] [11] This heterogeneity may be due to several unadjusted factors, including age-related differences in the disease stage at presentation, 4,9 in the treatments received, 10 in the spectrum of the treatment modalities used, 10, 12, 13 and in age-related baseline mortality rates. Furthermore, as both surgical and adjuvant treatments have evolved over time, institutional experiences accumulated over long periods further contribute to the varied findings. 14 Last, data derived from the clinical trials setting may not reflect variations in real-life clinical practice. 15, 16 To overcome these difficulties, we conducted a nationwide comparative cohort study to examine the relative survival of young adults with colon cancer, adjusting for variations in patient and tumor factors, comorbidities, disease stage, stage-specific treatments received, and baseline mortality rates. Because both cancer treatments and disease prognosis affect the experience of cancer survival, we examined age-related differences in the types and intensity of chemotherapy treatments, as well as differences in the relative survival gains. Our findings highlight the potential for unique survivorship care needs among young adults with colon cancer.
Methods

Study Setting and Data Source
We used the National Cancer Data Base (NCDB), a hospital-based nationwide cancer registry that is a joint program of the American College of Surgeons Commission on Cancer and the American Cancer Society. The NCDB captures more than 70% of all cancer diagnoses annually within the United States from almost 1500 accredited hospitals. Trained site-based cancer registrars collected and submitted all data using standardized coding definitions outlined by the Commission on Cancer's Facility Oncology Registry Data Standards manual. 17 Data quality assessments are performed using a combination of electronic and site-specific methods. 18 All data were deidentified. The University of Texas MD Anderson Cancer Center Institutional Review Board granted this study an exempt waiver for patient consent. 19, 20 Patients with known hereditary syndrome (familial adenomatous polyposis ICD-O-3 codes 8220-8221) were excluded. Also excluded were patients who did not receive curative-intent treatments and those with endoscopic or local tumor destruction only, with unknown or no surgery, or without information regarding the nature or timing of systemic chemotherapy. To further minimize bias, the study excluded patients younger than the Medicare-eligible age of 65 years, patients older than 75 years, patients who received postoperative systemic chemotherapy more than 6 months following surgery, and patients who received chemotherapy before surgery ( Figure 1) . The study cohort with young-onset colon cancer included 13 102 patients diagnosed between ages 18 and 49 years, reflecting the population diagnosed before the screening age of 50 years ( Figure 1 ). The comparative cohort included 37 007 patients diagnosed as having later-onset colon cancer aged 65 to 75 years, reflecting the age segment around 71 years, the median age at colon cancer diagnosis in the United States. 21 27 Unclassified facilities or other facilities were excluded ( Figure 1 ).
Patient Populations and Study Variables
Outcome Measures
The primary end point was relative survival, an established method of survival analysis in large patient registries. Relative survival is defined as the ratio of observed survival (all causes of death) for a cohort of patients with cancer to the expected survival of a comparable cohort of the general population without cancer. It provides an objective measure of survival among patients with cancer, adjusting for baseline mortality rates and independent of the data on cause of death. [28] [29] [30] A secondary end point was the likelihood of receiving postoperative systemic chemotherapy.
Statistical Analysis
Descriptive statistics included the median and interquartile range for continuous variables and the number and frequency for discrete variables. χ 2 Test was used to compare categorical variables by age group (18-49 years and 65-75 years). Multivariable logistic regression models assessed the association between age groups and receipt of systemic chemotherapy, adjusting for all other patient and tumor factors. Odds ratios (ORs) with 95% CIs were generated. Relative survival was determined from the year of diagnosis by calculating the ratio of observed survival to expected survival rates of the similar sex-and age-matched US population. 28 Population survival data were obtained from the Human Mortality Database. 31 Five-year relative survival rates and 95% CIs were calculated and stratified by age group and by disease stage. The effect of young age on relative survival was analyzed by multivariable relative survival analysis for each disease stage using generalized linear models and assuming a Poisson distribution for the observed number of deaths. 32 Multivariable relative survival models were further stratified by receipt of chemotherapy. Adjusted relative risk of death was expressed as relative risk with a 95% CI. All reported P values were 2-sided, and P < .05 was considered statistically significant. Bonferroni adjustment for multiple comparisons of patient characteristics did not alter statistical significance. All statistical analyses were performed with a software program (STATA 11 MP; StataCorp LP).
Results
Patient and Tumor Factors Associated With Young-Onset and Later-Onset Colon Cancer
More patients with young-onset vs later-onset colon cancers were of nonwhite race/ethnicity and had no health insurance. We also observed variations in the median household income and in the region of residence. Most patients were healthy, with a Charlson-Deyo Comorbidity Index of 1 or less ( Table 1) .
More young-onset colon cancers were initially seen with nodal or distant metastases: 36.5% and 25.3% of young-onset tumors were stage III and stage IV, respectively, while 30.3% and 15.7% of later-onset tumors were stage III and stage IV, respectively (P < .001) ( Table 1) . Young-onset colon cancer had a propensity toward the distal colon, while later-onset colon cancer was seen more frequently in the proximal colon. Poor differentiation and signet ring cell and mucinous features were slightly more common among young-onset cases.
Younger patients were more frequently treated at academic or research facilities than at community cancer programs (Table 1) . Surgical resection was performed in all patients in this study. However, postoperative systemic chemotherapy was administered in 66.3% of young adults with colon cancer but in only 39.8% of the older patients.
Oncologic Treatments: Stage-Specific Adjusted Multivariable Analysis
After adjusting for patient and tumor factors as well as disease stage, young adults remained much more likely to receive chemotherapy in each stage (Table 2) . Specifically, adjuvant chemotherapy is not the standard of care in stage II disease, but we observed the highest OR for receipt of chemotherapy among young adults, with ORs of 2.88 for stage I, 4.22 for stage II low risk, and 3.93 for stage II overall. Almost 6% of the patients with young-onset stage I disease received adjuvant chemotherapy. Adjuvant chemotherapy was administered to 50.5% of the young patients vs 19.1% of the older patients with stage II low-risk disease.
Furthermore, among patients who received adjuvant chemotherapy, young adults were more likely to receive multiagent regimens (likely oxaliplatin or irinotecan based) rather than single-agent regimens. For patients with stage II, III, and IV disease, these ORs were 1.71, 1.75, and 1.90, respectively (Table 2) .
Relative Survival for Young Adults With Colon Cancer: Stage-Specific Adjusted Multivariable Analysis
The median follow-up was 6.3 years (interquartile range, 5.4-7.2 years). The unadjusted survival analysis showed slightly inferior 5-year relative survival for the young adults (0.66 vs 0.69, P < .001) (Figure 2) . However, this trend no longer held in a comparison of patients receiving the same stage-specific treatments, adjusting for patient and tumor factors ( Table 3) . Young vs older patients with stage I colon cancer treated with surgery alone were also compared. The adjusted 5-year relative survival was more favorable for younger patients.
For young vs older patients with stage II disease treated with surgery alone, young adults again showed more favorable survival (86.9% vs 82.3%) (Table 3) , particularly for those with low-risk disease. On the other hand, the survival of young adults treated with surgery plus adjuvant chemotherapy did not significantly differ from that of their older counterparts. The 5-year relative survival of young adults vs older adults was 91.1% vs 90.2% for stage II overall, 95.2% vs 95.4% for stage II low risk, and 87.7% vs 85.8% for stage II high risk (Figure 3) .
In stage III and IV disease, young patients who received postoperative systemic chemotherapy demonstrated only marginally more favorable survival outcomes than older patients who received the same treatments. These ORs were 0.89 for stage III and 0.84 for stage IV (Figure 3 ).
Discussion
Colon cancer is increasing among adults younger than 50 years.
3,4, 6 The objective of this study was to define the prognosis of young adults with colon cancer outside of the clinical trials setting, adjusting for significant age-related variations in disease stage and in treatment administration using reallife data across the United States. In this largest such comparative cohort study to date, we demonstrated that young adults are 2 to 4 times more likely to receive systemic chemotherapy after surgical resection than older patients in each disease stage, including stage I and stage II low risk, for which adjuvant therapy is not the standard of care. In particular, young adults were more likely to receive multiagent oxaliplatin-based or irinotecan-based regimens. Moreover, these more intense treatments did not result in significant survival gains relative to those of their older counterparts. This mismatch in oncologic treatment administration vs relative survival highlights overtreatment of young adults with colon cancer and the potential for increased risks of treatment-associated toxicities for young cancer survivors. To our knowledge, this is the largest study to date examining the relative survival of young adults with colon cancer in a large nationwide cohort that reflects real-life practices out- vival analysis showed poorer prognosis for young patients.
However, the significantly more advanced stages at diagnosis among young adults (an unscreened population) cannot be overemphasized. Indeed, after adjusting for disease stage, their prognosis was equivalent or slightly better compared with older adults, consistent with other studies. 8, 9, 16 Another populationbased study 9 cer. That study found similar survival for stage I and stage III disease but better survival for stage II and stage IV disease among the young, although the findings were not adjusted for differences in comorbidities, treatments, or baseline mortality rates. Our results suggest that the prognostic effect of young age must be interpreted after adjusting for age-related disparities in patient, tumor, and treatment factors. Prior disparities investigations have mostly focused on the elderly, suggesting possible undertreatment, and did not examine young adults with cancer. 33 We found that almost 6%
of the young adults with stage I disease and more than half of those with stage II disease (regardless of low or high risk) received postoperative systemic chemotherapy. These practices represent overtreatment because current evidence does not support chemotherapy in stage I disease and indicates a controversial role of chemotherapy in stage II disease. 26 Indeed, these observations corroborate prior single-institution studies 10, 13 showing that young adults with rectal cancer receive more chemotherapy and pelvic irradiation and that young patients with colon cancer receive more adjuvant therapy, even for node-negative disease. Thus far, data regarding chemotherapy in young adults with colon cancer have been limited to those from clinical trials. 15, 16 We found that young adults were more likely to receive multiagent regimens at all stages of disease (Table 2) . Indeed, patient demands, physician attitudes, or the perceived ability for young adults to tolerate more treatment may have driven these practices. However, although more young patients were subjected to the intense regimens, their relative survival was equivalent or only marginally more favorable than that of the older patients. The potential for treatment-related toxicities cannot be overlooked. Long-term data from the National Surgical Adjuvant Breast and Bowel Project C-07 trial and the Multicenter International Study of Oxaliplatin/ 5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer have shown a 10% to 15% rate of persistent peripheral sensory neuropathy and a 3% rate of persistent toxicities that interfere with activities of daily living after multiagent chemotherapy. [34] [35] [36] [37] In summary, in the absence of clear superiority in treatment efficacy, a large proportion of young patients are being subjected to treatments with potential longterm toxicity. The long-term effect of this practice pattern on the experience of cancer survival among young adults with colon cancer warrants investigation. Our study has some limitations. First, tumor molecular characteristics and long-term toxicity data were not available in the nationwide cancer registry. One may postulate that young patients disproportionately received multiagent (rather than 5-fluorouracil only) chemotherapy because their tumors were mostly mismatch repair deficient. 38, 39 However, mismatch repair deficiency and Lynch syndrome account at most for only 20% of all colon cancers before age 50 years. [40] [41] [42] Therefore, mismatch repair status (although not available herein) cannot account for the observed age-related treatment disparity. Second, the survival analysis could not be adjusted for by molecular prognostic biomarkers. KRAS and BRAF mutations may be prognostically important, but whether their prevalence differs by age has not been definitively established. 43 Third, our data among patients with stage IV disease must be interpreted with significant caution because we included only those who underwent surgical resection of the primary colon cancer. Therefore, they represent a highly select subgroup of patients with stage IV colon cancer.
Conclusions
In conclusion, adults younger than 50 years represent the only population segment in which the CRC incidence is rising. We identified evidence for overtreatment of young adults with colon cancer, particularly those with stage I disease and stage II low-risk disease. On the other hand, the adjusted stagespecific prognosis did not differ (for stage II disease) or was only minimally superior (for stage III and stage IV disease) for youngonset vs later-onset colon cancers. The minimal survival differences were unmatched by the significantly greater patterns of overtreatment in the young. We highlight the potential for lingering treatment-associated toxicities in young cancer survivors and suggest that their potentially unique survivorship warrants specific investigation.
